Wegovy
Obesity drug
Semaglutide for chronic weight management in adults and teens with obesity, sold as a weekly injection and, since 2026, a daily pill.
Obesity drugSince 2021
How it started
Semaglutide reworked for obesity.
2021the year it started
Novo Nordisk tested a higher dose of its own semaglutide in the STEP trials and won US FDA approval for Wegovy in June 2021.
How big it is
How big is Wegovy?
DKK 79.1BWegovy salesFY2025
Its place in Novo Nordisk
One in four Novo Nordisk kroner.
25.6%of Novo Nordisk salesFY2025
Wegovy is the engine of Novo's Obesity care business, its second-largest product after Ozempic.
Who it competes with
ZZepbound (Lilly)MMounjaro (Lilly)
What Novo Nordisk does not disclose
- Wegovy operating profit
- Number of people treated with Wegovy
- Wegovy pill sales on their own
- Net price per prescription
The group behind itNovo Nordisk
→
Sources
Every number on this page comes from Novo Nordisk's own reports.
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
